Click here to view the United Healthcare (UHC) Medical Policy Updates » December 2024 United…
BCBS Tennessee Medical Policy Updates – September 2018
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »
September 2018 BCBS Tennessee Medical Policy Updates:
- Abatacept
- AbobotulinumtoxinA
- Agalsidase Beta
- Alemtuzumab
- Alglucosidase Alfa
- Angioplasty and/or Stenting for Intracranial Arterial Disease (IAD)
- Applied Behavioral Analysis (ABA)
- Atezolizumab
- Autonomic Nervous System Testing
- Avelumab
- Bariatric Surgery
- Belimumab
- Belinostat
- Bendamustine HCl (Bendeka®)
- Bendamustine HCl (Treanda®)
- Benralizumab
- Bevacizumab for the Treatment of Neoplastic Disease
- Bioengineered Skin and Soft Tissue Substitutes
- Blinatumomab
- Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Other Diseases Associated with High Bone Turnover
- Brentuximab Vedotin
- C1 Esterase Inhibitor (Berinert®)
- C1 Esterase Inhibitor (Cinryze®)
- C1 Esterase Inhibitor (Ruconest®)
- C1 Esterase Inhibitor, Human (Berinert )
- C1 Esterase Inhibitor, Human (Cinryze®)
- Canakinumab
- Certolizumab Pegol
- Cetuximab
- Computer Assisted Surgical Navigation for Orthopedic Procedures
- Computer-Aided Detection of Malignancy with Magnetic Resonance Imaging of the Breast
- Computerized 2-lead Resting Electrocardiogram Analysis for the Diagnosis of Coronary Artery Disease
- Conjunctival Challenge Test
- Cytologic Evaluation in Breast Cancer Risk Assessment
- Daratumumab
- Darbepoetin Alfa
- Daunorubicin and Cytarabine Liposome for Injection
- Denosumab
- Dexamethasone Intravitreal Implant
- Diagnosis and Treatment of Facet Joint Pain
- Durvalumab
- Electrical Stimulation for the Treatment of Arthritis
- End Diastolic Pneumatic Compression Boot as a Treatment of Peripheral Vascular Disease or Lymphedema
- Epoetin Alfa
- Epoetin Alfa-epbx
- Eribulin Mesylate
- Erythropoiesis Stimulating Agents (ESAs): Darbepoetin Alfa
- Erythropoiesis Stimulating Agents (ESAs): Darbepoetin Alfa
- Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa
- Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa
- Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
- Fluocinolone Acetonide Intravitreal Implant for the Treatment of Uveitis
- Fosnetupitant / Palonosetron
- Functional Magnetic Resonance Imaging
- Genetic Testing (CFTR mutations) for Cystic Fibrosis
- Golimumab for Intravenous Infusion
- Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas
- Histrelin Acetate for Central Precocious Puberty (CPP)
- Histrelin Acetate Implant for Prostate Cancer
- Home Nutritional Support (Total Parenteral / Enteral Nutrition)
- Imiglucerase
- Implantable Hypoglossal Nerve Stimulation
- IncobotulinumtoxinA
- Infliximab
- Infliximab-dyyb
- Intradiscal Annuloplasty for Treatment of Discogenic Back Pain
- Irinotecan Liposome Injection
- Ixabepilone
- Keratoprosthesis
- Kinesio Taping
- Laboratory Tests for Heart Transplant Rejection
- Laronidase
- Leukocyte Histamine Release Test (LHRT)
- Leuprolide Acetate for Depot Suspension
- Levoleucovorin
- Liposuction
- Mammography Screening
- Natalizumab
- Negative Pressure Wound Therapy in the Outpatient Setting
- Neuromuscular Electrical Stimulation
- Non-invasive Positive Pressure Ventilators (In-Home Use)
- Noninvasive Techniques for Evaluation and Monitoring of Chronic Liver Diseases
- Ocrelizumab
- Octreotide Acetate Long-Acting Dosage Form
- OnabotulinumtoxinA
- Panitumumab
- Pegfilgrastim
- Pembrolizumab
- Plugs for Anal Fistula Repair
- Positron Emission Mammography
- Positron Emission Tomography (PET) for Miscellaneous Applications
- Prostate Specific Antigen (PSA)
- Proteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses
- Pulmonary Arterial Hypertension Agents
- Reduction Mammoplasty (Non-Cancerous)
- Rhinoplasty
- RimabotulinumtoxinB
- Rituximab
- Rituximab and Hyaluronidase Human Injection
- Romidepsin
- Serum Biomarker Human Epididymis Protein 4 (HE4)
- Sipuleucel-T
- Spinal Cord Stimulation for the Treatment of Pain
- Stereotactic Radiosurgery of Central Nervous System (CNS) Lesions
- Subcutaneous Immune Globulins
- Surface Electromyography (sEMG)
- Temsirolimus
- Testosterone Testing
- Tisagenlecleucel
- Tocilizumab (Intravenous)
- Tocilizumab (Intravenous)
- Transcranial Magnetic Stimulation (TMS)
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transpupillary Thermotherapy (TTT)
- Transtympanic Micropressure Applications as a Treatment of Ménière’s Disease
- Trastuzumab
- Treatment of Congenital Port Wine Stains and Hemangiomas
- Triptorelin Pamoate
- Urinary Tumor Markers for Bladder Biomarkers for Cancer Screening, Diagnosis, and Surveillance
- Vedolizumab
- Vedolizumab
- Voretigene Neparvovec-rzyl
- Vulvectomy
- Ziv-Aflibercept
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
